Injectable Platelet Rich Fibrin With Collagen Matrix in Treatment of Multiple Gingival Recession.
Study Details
Study Description
Brief Summary
This study is proposing the use of i-PRF clot as a scaffold for the XCM in order to obtain a novel biomaterial, incorporating active growth factors and collagen matrix in a single framework, based on the potential effect of i-PRF to enhance fibroblast activity and angiogenesis stimulation for treatment of multiple gingival recession.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Control arm Patients with Gingival recessions are type 1 recession RT1 (cairo et al,2011) which correspond to Miller I&II gingival recession. |
Procedure: CAF+CM
Periodontal surgery including CAF+CM application
|
Other: Experimental arm Patients with Gingival recessions are type 1 recession RT1 (cairo et al,2011) which correspond to Miller I&II gingival recession. |
Procedure: CAF+CM
Periodontal surgery including CAF+CM application
Procedure: I-PRF
Periodontal surgery including CAF+CM application with i-PRF
|
Outcome Measures
Primary Outcome Measures
- Reduction in gingival recession depth on the buccal sides of type one gingival recessionRT1 [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]
The primary outcome of the study is the reduction in gingival recession depth on the buccal sides of RT1 gingival recession, between the baseline preoperative measurement and follow-up at 3 months and 6 months. The Recession Depth (RD) is Measured in millimeter (mm) from CEJ (Cemento-Enamel-Junction) to the gingival margin using UNC-15 probe.
Secondary Outcome Measures
- Improvement in Gingival Thickness (GT) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]
Gingival Thickness (GT) is determined at 1.5 mm apical to the gingival margin using a caliper (endodontic reamer#20) rounded to the nearest 0.1mm.
- Improvement in the Keratinized Tissue Height (KTH) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]
Keratinized Tissue Height (KTH) is measured in millimeters (mm) taken at the mid buccal aspect of the involved teeth from the gingival margin to the muco-gingival junction, by a manual periodontal probe (UNC-15 probe,Hu-Friedy,Chicago,USA).
- Reduction in the Recession Width (RW) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]
Recession Width (RW) is measured in millimeter (mm) at the Cement-Enamel Junction (CEJ) using UNC-15 probe.
- Reduction in Probing Pocket Depth (PPD) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]
Probing Pocket Depth (PPD) is measured in millimeter (mm) from the gingival margin to the apical extend of the probe.
- Reduction Clinical Attachment Level (CAL) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]
Clinical Attachment Level (CAL) is measured in millimeter (mm) from the CEJ to the apical extend of the probe.
- Measuring Plaque-Index (PI) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]
Plaque-Index (PI) is measured as a percentage of the presence of Plaque on four surfaces of the teeth using a manual periodontal probe.
- Measuring Bleeding On Probing (BOP) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]
Bleeding On Probing (BOP) is measured as a percentage of sites with bleeding on probing using a manual periodontal probe.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Presence of at least two localized gingival recessions on either sides of the maxilla and/or mandible excluding molar region.
-
The cemento-enamel junction (CEJ) is visible in the teeth for root coverage procedures.
-
All recessions are type 1recession RT1 (cairo et al,2011) which correspond to Miller I&II gingival recession
-
All patients must demonstrate adequate plaque control with a fullmouth plaque score less than 20% and with .
-
All patients at least 18 years of age and of both genders.
Exclusion Criteria:
-
Smoker Patients .
-
Patients with diabetes.
-
Patients with a history of malignancy, radiotherapy, or chemotherapy for malignancy.
-
pregnant or nursing women.
-
Patients taking medications or having treatments with an effect on mucosal healing in general (e.g. steroids, large doses of antiinflammatory drugs).
-
Patients with a disease affecting connective tissue metabolism.
-
Patients allergic to collagen.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Baghdad / College of Dentistry | Baghdad | Iraq | 10047 |
Sponsors and Collaborators
- University of Baghdad
Investigators
- Principal Investigator: Basima Gh Ali, MSc, University of Baghdad / College of Dentistry
- Study Director: Thair AL Hassan, PHD, University of Baghdad / College of Dentistry
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 519622